Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics...( DALLAS May 28 /- ACCESS PHARMACEU...),Health

DALLAS, May 28 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that the company gave oral and poster presentations on its Cobalamin(TM) technology at the International Symposium on Polymer Therapeutics: Laboratory to Clinical Practice, taking place from May 26-28 in Valencia, Spain. The presentations are entitled "Vitamin B12-Polymer Conjugates as Constructs for Targeted Tumor Delivery and for Oral Drug Delivery."

Cobalamin is Access' proprietary technology based upon the use of vitamin B12 for targeted delivery of drugs to disease sites and for oral drug delivery of drugs that otherwise have poor oral bioavailability. The presentations provide new data showing that Cobalamin-coated nanoparticles can provide a substantial lowering of blood glucose levels in an animal model of diabetes when compared with unformulated insulin given orally, and glucose-lowering effect which has much greater duration when compared with using insulin given subcutaneously. In addition, data are presented which shows that Cobalamin- targeted polymer-linked daunorubicin reduces tumor volume following intravenous administration in an animal model, providing superior efficacy when compared to polymer-daunorubicin without the targeting group, and substantially superior efficacy to daunorubicin alone.

"These new data provide strong evidence that our Cobalamin technology can be very effective in two important areas of drug development, and demonstrate that Cobalamin technology has the potential to provide a pipeline of new products in the future," commented David P. Nowotnik, PhD, Access' Senior Vice President of R&D, who presented the data at the Symposium. Dr. Nowotnik continued, "Development of an oral insulin formulation that can be moved forward rapidly into clinical development remains one of main R&D objectives." Access is also developing a Cobalamin oral formulation for human growth hormone in a research program spons
'/>"/>